DiaMedica's initial product candidate, DM199, mimics the behavior of naturally occurring human KLK1 proteins to preserve and restore circulation to stroke-damaged tissue and improve overall kidney function.

In July 2022, the US Food and Drug Administration placed a clinical hold on the Phase II/III ReMEDy2 trial studying the use of DM199 in acute ischemic stroke.